Sign In
Buy HALO
$82.54
-0.760 (-0.91%)
At Close: Jul 31, 2026
This Medical Technology Stock Claws Back To A Buy Zone
01:50pm, Wednesday, 29'th Jul 2026
This medical technology name has a patented method of drug delivery. Halozyme stock recently hit a record high with earnings due out soon.
Halozyme: Unique Business Model -- Adds A Powerful Leavening Element To Any Biotech Portfolio
11:28am, Wednesday, 29'th Jul 2026
Halozyme (HALO) has delivered ~134% price appreciation since my prior 'Buy' rating in 06/2023. I evaluate whether HALO can sustain its strong growth trajectory or is due for a period of consolidation.
Halozyme Therapeutics (NASDAQ:HALO) Hits New 52-Week High – Here’s What Happened
02:02am, Sunday, 26'th Jul 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) shares reached a new 52-week high on Friday. The company traded as high as $82.99 and last traded at $81.5140, with a volume of 217609 shar
Halozyme to Report Second Quarter 2026 Financial and Operating Results
08:30am, Thursday, 23'rd Jul 2026
SAN DIEGO, July 23, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its second quarter 2026 financial and operating results on Thursday, Au
Halozyme's Partnerships, Earnings Growth See Shares Near All-Time Highs
07:21am, Wednesday, 22'nd Jul 2026
Halozyme Therapeutics, Inc. (HALO) shares gain 539% since first Big Money outlier inflow signal in March 2014.
HALO Inks Deal With INCY to Support Cancer Therapy Development
11:40am, Tuesday, 21'st Jul 2026
Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients.
Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targets SAN DIEGO, July 20, 2026 /PRNews
Fifth Third Bancorp Grows Position in Halozyme Therapeutics, Inc. $HALO
04:05am, Sunday, 19'th Jul 2026
Fifth Third Bancorp increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 4,206.4% during the first quarter, according to its most recent filing with the Securities and Exchange Comm
Inflation Cools But US-Iran Tensions Rise: 4 Value Stocks to Buy Now
11:36am, Thursday, 16'th Jul 2026
ARCO, HALO, TX and ARRY screen as high-earnings-yield value picks as the Middle-East conflict sharpens stock selection.
Time for HALO Sectors & ETFs?
10:37am, Thursday, 16'th Jul 2026
HALO stocks are gaining favor as investors rotate toward tangible assets and AI-resistant businesses. Here are ETFs to play the trend.
Time to Buy Wide Moat & HALO ETFs?
12:00pm, Friday, 10'th Jul 2026
Wall Street is caught in the midst of shifting geopolitical stances of the United States and Iran, chances of higher global inflation, weak U.S. jobs data, the possibility of stagflation in the U.S. e
Halozyme Appoints David Ramsay as President Drug Delivery
04:02pm, Tuesday, 30'th Jun 2026
SAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery, effective
SAN DIEGO, June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?
12:31pm, Wednesday, 10'th Jun 2026
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Anti-AI Investing: The HALO Moat Goes Off The Rails
08:02am, Tuesday, 09'th Jun 2026
North American railroads like UNP, NSC, CSX, CNI, and CP exhibit HALO traits: irreplaceable heavy assets, low obsolescence, and durable cash flows. Current railroad valuations are rich, with multiples
